Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO) - PubMed
7 hours ago
- #AML
- #Clonal evolution
- #FLT3 mutations
- Study examines clonal evolution and outcomes in AML patients from diagnosis to relapse/refractory disease.
- 650 patients included: 172 FLT3-positive (FLT3pos) and 472 FLT3-negative (FLT3neg).
- At first occurrence, FLT3 testing rate decreased to 57.0% (166/291).
- Gain or loss of FLT3 mutations observed in 15.6% of FLT3pos and 14.9% of FLT3neg patients.
- Median overall survival: 22.8 months (FLT3pos not estimable, FLT3neg 20.3 months).
- FLT3pos status at baseline associated with improved outcomes, but not at first occurrence.
- Timely FLT3 mutation retesting may help personalize treatment.
- Study adheres to ethical guidelines with informed consent from all patients.